Data updated: Mar 10, 2026
LYTGOBI
FUTIBATINIB
Approved 2022-09-30
1
Indication
--
Phase 3 Trials
1
Priority Reviews
3
Years on Market
Details
- Status
- Prescription
- First Approved
- 2022-09-30
- Routes
- ORAL
- Dosage Forms
- TABLET
LYTGOBI Approval History
Loading approval history...
What LYTGOBI Treats
1 FDA approvalsOriginally approved for its first indication in 2022 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LYTGOBI FDA Label Details
ProLYTGOBI Patents & Exclusivity
Latest Patent: Nov 2039
Exclusivity: Sep 2029
Patents (12 active)
US11833151
Expires Nov 5, 2039
US10434103
Expires Mar 31, 2036
US9108973
Expires Feb 13, 2033
+ 2 more patents
Exclusivity
NCE
Until Sep 2027
ODE-410
Until Sep 2029
NCE
Until Sep 2027
ODE*
Until Sep 2029
NCE
Until Sep 2027
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.